Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|June 29, 2017

Pharmapack Europe Returns to EU in 2018

The conference will return to the EU and is featuring its Start-Up Hub and Pharmapack Awards.

Pharmapack Europe will return to the European Union on February 7–8, 2018 at the Paris Expo Porte de Versailles, Paris. The conference is currently calling for new applications to its start-up hub platform and for the Pharmapack Awards. The 2018 Start-up Hub is meant to identify innovative new companies.

Start-ups in the inaugural 2017 Start Up Hub spanned the industry; from functional inks that incorporate electronic applications to packaging, to needle-free medicine delivery, to an application that scans packages to provide product information. For 2018, start-ups developing patient-centric packaging or drug delivery solutions in line with connected health and anti-counterfeiting measures are encouraged to apply.

The Pharmapack Awards will also return in 2018. The awards consist of two categories; the Exhibitor Innovation category and, for non-exhibitors, the Health Product category. Exhibitors that take part in the Innovation Gallery automatically enter the Awards for this category, but will still need to complete an entry document for a chance to win.

Pharmapack Award applications are now open for 2018 to companies providing new products. Applications for the 2018 Pharmapack Awards are open until Nov. 3, 2017.

Source: Pharmapack Europe 


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.